

CLINICAL RESEARCH ARTICLE

OPEN



Functional response to a microbial synbiotic in the gastrointestinal system of children: a randomized clinical trial

Braden T. Tierney^{1,2}, James Versalovic^{3,4}, Alessio Fasano⁵, Joseph F. Petrosino⁶, Bruno P. Chumpitazi^{7,8}, Emeran A. Mayer^{9,10}, Jared Boetes², Gerard Smits², Shanthi G. Parkar², Noah Voreades², Ece Kartal¹¹, Gabriel A. Al-Ghalith², Marco Pane², Peter A. Bron², Gregor Reid^{12,13}, Raja Dhir²✉ and Christopher E. Mason¹✉

© The Author(s) 2022

BACKGROUND: Oral microbial therapy has been studied as an intervention for a range of gastrointestinal disorders. Though research suggests that microbial exposure may affect the gastrointestinal system, motility, and host immunity in a pediatric population, data have been inconsistent, with most prior studies being in neither a randomized nor placebo-controlled setting. The aim of this randomized, placebo-controlled study was to evaluate the efficacy of a synbiotic on increasing weekly bowel movements (WBMs) in constipated children.

METHODS: Sixty-four children (3–17 years of age) were randomized to receive a synbiotic ($n = 33$) comprising mixed-chain length oligosaccharides and nine microbial strains, or placebo ($n = 31$) for 84 days. Stool microbiota was analyzed on samples collected at baseline and completion. The primary outcome was a change from baseline of WBMs in the treatment group compared to placebo.

RESULTS: Treatment increased ($p < 0.05$) the number of WBMs in children with low baseline WBMs, despite broadly distinctive baseline microbiome signatures. Sequencing revealed that low baseline microbial richness in the treatment group significantly anticipated improvements in constipation ($p = 0.00074$).

CONCLUSIONS: These findings suggest the potential for (i) multi-species-synbiotic interventions to improve digestive health in a pediatric population and (ii) bioinformatics-based methods to predict response to microbial interventions in children.

Pediatric Research; <https://doi.org/10.1038/s41390-022-02289-0>

IMPACT:

- Synbiotic microbial treatment improved the number of spontaneous weekly bowel movements in children compared to placebo.
- Intervention induced an increased abundance of bifidobacteria in children, compared to placebo.
- All administered probiotic species were enriched in the gut microbiome of the intervention group compared to placebo.
- Baseline microbial richness demonstrated potential as a predictive biomarker for response to intervention.

BACKGROUND

Recent advances in microbiome tools (e.g., culturing, bioinformatics) have enabled a deeper understanding of microbial ecology and the gut microbiome's role in human health. Gastrointestinal microbes exert functional influence on the host through a range of metabolic and immunological mechanisms, and the host shapes resident microbial communities through diet, nutrition, lifestyle, and medication.^{1–3} The composition of the human gut microbiome has been identified as playing a role in regulating bowel movements in children.

This includes functional constipation (FC), which is characterized by infrequent bowel movements and associated phenotypes therein (e.g., stool consistency, pain when defecating, bloating).^{4–9} FC afflicts about 25% of children visiting pediatric gastroenterologist practices in the United States.¹⁰ Symptoms of pediatric FC frequently persist into adolescence and adulthood despite treatment with laxatives, indicating the need for alternative treatment paradigms.¹¹

Gut microbiota are suggested to influence bowel movement frequency through multiple mechanisms. These include ligand-

¹Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA. ²Seed Health, Venice, CA, USA. ³Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA. ⁴Department of Pathology, Texas Children's Hospital, Houston, TX, USA. ⁵Mucosal Immunology and Biology Research Center, Center for Celiac Research and Treatment and Division of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital for Children, Boston, MA, USA. ⁶Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. ⁷Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. ⁸Neurogastroenterology and Motility Program, Texas Children's Hospital, Houston, TX, USA. ⁹Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. ¹⁰G Oppenheimer Center for Neurobiology of Stress and Resilience, Los Angeles, CA, USA. ¹¹Institute for Computational Biomedicine, Heidelberg University Hospital, Heidelberg, Germany. ¹²Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, London, ON, Canada. ¹³Departments of Microbiology and Immunology and Surgery, Western University, London, ON, Canada.

✉email: raja@seed.com; chm2042@med.cornell.edu

Received: 22 April 2022 Revised: 23 July 2022 Accepted: 29 July 2022

Published online: 02 November 2022

receptor type interactions with the competitive exclusion of pathogens, generation of antibacterial substances, setting an anti-inflammatory tone to the gut environment, signaling effects that influence the enteric nervous system, and breakdown of fiber to generate short-chain fatty acids that improve gut function.^{12–15} As a result, modulation of the gut microbiota in children may lead to beneficial clinical outcomes for those experiencing bowel distress.

A number of pilot studies have been conducted to identify if microbial therapies can improve the quantity and quality of weekly bowel movements (WBMs). These have included supplementation of live bacteria (i.e., candidate probiotics), ingredients to support the growth of beneficial organisms (i.e., prebiotics), or a combination of the two (i.e., synbiotics). In children, an intake of inulin-type fructans has been associated with softer stool consistency¹⁶ (a component of FC) as well as protection against gastrointestinal infection,¹⁷ antibiotic-induced bifidobacterial depletion,¹⁸ weight gain,¹⁹ and mineral malabsorption.²⁰ At least some of these benefits are attributed to fructan-mediated bifidogenic effect.^{17,21} The by-products of bifidobacterial metabolism, predominantly organic acids, are further known to cross-feed secondary feeders, mainly butyrogenic bacteria from *Lachnospiraceae* and *Ruminococcaceae*.^{22,23} The increase in a more diverse microbiome helps to build a greater heterofermentative capacity, thus nurturing a more beneficial microbial consortium.

For specific strains, there have been statistically significant, beneficial outcomes in human trials.^{24,25} Specific genera of interest empirically include *Lactobacillus*, *Lactocaseibacillus*, *Ligilactobacillus*, and *Bifidobacterium*.^{26,27} For prebiotics, fiber—which is a key microbial nutritional substrate—is potentially effective in improving bowel movement frequency, especially in children.^{28–30} That said, meta-analyses evaluating the relationship between nutritional inputs and constipation relief showed substantial heterogeneity in results.^{27,31,32} However, these studies have predominantly been in non-pediatric cohorts, they have lacked a placebo arm, and they tend to use single-organism interventions.^{33,34}

Consequently, there is a need to test in placebo-controlled trials the efficacy of microbial therapies in reducing pediatric constipation and its associated symptoms. Here, we do so in a pilot study

to determine the impact of a nine-strain (eight species) synbiotic (a prebiotic and defined microbial consortium) formulation (with the prebiotic comprising mixed-chain length oligosaccharides) on ameliorating constipation.

METHODS

Study design and primary objective

The clinical trial was IRB-approved, multicenter, randomized, double-blind, and placebo-controlled with two parallel arms (ClinicalTrials.gov identifier NCT04534036). Following a run-in period of 14 days, subjects were randomly assigned to an intervention and placebo arm for a duration of 84 days. “Constipated” was defined as having fewer than four WBMs, whereas “low WBMs” was a superset of this group, defined as having fewer than five WBMs. The primary objective of the study was to assess the change from baseline to day 84 in the weekly frequency of spontaneous bowel movements between subjects receiving placebo and those receiving a multistrain synbiotic.

Randomization and patient selection

A standardized treatment effect of 0.6 in Bristol Stool Form Scale change was estimated. Based on this anticipated treatment effect, a sample size of 43 per arm was needed to achieve 85% power. This number was increased to >100 to account for attrition. In total, 121 healthy male/female subjects were assessed for eligibility (Fig. 1, Supplementary Fig. S1, and Supplementary Table S1). Exclusion criteria included obesity, pregnancy, lack of parental consent or ability to collect data during the study, and a lack of medical history. Thirty subjects were excluded due to exclusionary self-reported medications or body mass index measurements. The remainder underwent a 14-day run-in to establish baseline WBMs as a 7-day average with daily reporting. Variation was observed in the parental reported baseline WBMs during the 14-day run-in period. The results showed a heterogeneous pediatric population with highly variable baseline WBM frequency, and many subjects did not meet our definition of constipation (Table 1). Of the 64 subjects who completed through day 84, 38 had fewer than 5 WBMs, and 21 had less than 4 WBMs.

Allocation, randomization, blocking, and blinding were executed by a Contract Research Organization. 1:1 randomization was done via a computer-generated sequence (with the expectation of normal age distribution in the active and placebo groups) using two strata (male vs. female) and block sizes of 2, 4, and 6. The randomization resulted in 43 subjects in the synbiotic arm and 48 receiving placebo. Parents




Fig. 1 Randomized, placebo-controlled clinical design. CONSORT diagram indicating clinical trial design and execution.

Table 1. Cohort characteristics.

	Placebo (N = 31)	Active (N = 33)	Overall (N = 64)
Baseline WBM			
Mean (SD)	5.26 (2.60)	6.83 (7.60)	6.07 (5.76)
Median [min, max]	4.20 [0.700, 11.2]	4.20 [1.40, 42.0]	4.20 [0.700, 42.0]
Endpoint WBM			
Mean (SD)	6.55 (4.40)	8.80 (7.93)	7.71 (6.52)
Median [min, max]	7.00 [0, 17.5]	7.00 [0, 42.0]	7.00 [0, 42.0]
Age			
Mean (SD)	9.84 (3.87)	7.79 (3.25)	8.78 (3.68)
Median [min, max]	9.00 [3.00, 17.0]	7.00 [3.00, 14.0]	8.00 [3.00, 17.0]
Sex			
Female	15 (48.4%)	12 (36.4%)	27 (42.2%)
Male	16 (51.6%)	21 (63.6%)	37 (57.8%)

reported in a logbook the daily frequency and consistency of their child's stool and any adverse events or use of medications. The subjects were asked to not consume any additional probiotic supplements or foods during the study period. WBMs were reported to the study coordinators twice weekly throughout the 84-day intervention period. While first-dosing was administered in 91 children, 27 children did not complete through day 84. These study participants or their legal guardian(s) received a termination notice upon which clinical product or placebo was returned to the study coordinator for prompt disposal. All data for these non-completing 27 children at baseline were dropped from the analysis and baseline microbiome samples were destroyed.

Intervention

The interventional composition consisted of 6.2 g of mixed-chain length prebiotic substrates suspended in a single sachet with nine microbial strains ($>10^{10}$ CFUs) (and within them, eight species): *Bifidobacterium breve* SD-B632-IT, *Bifidobacterium breve* SD-BR3-IT, *Bifidobacterium lactis* SD-Bi07-US, *Bifidobacterium lactis* SD-CECT8145-SP, *Bifidobacterium longum* SD-CECT7347-SP, *Lactocaseibacillus casei* SD-CECT9104-SP, *Lactocaseibacillus rhamnosus* SD-GG-BE, *Ligilactobacillus salivarius* SD-LS1-IT, and *Lactobacillus acidophilus* SD-NCFM-US. The placebo was composed of weight-, color-, and taste-matched tapioca maltodextrin and fructose. Both active and placebo were packaged in identical, unmarked sachets and shipped directly to the subject's home to be administered daily under the supervision of the child's legal, consenting guardian.

Statistical analysis of clinical data

Analyses of clinical outcomes were performed using SAS³⁵ software, version 9.4. Plots were produced using R³⁶ version 4.1.1. Descriptive summaries included the mean, standard deviation, median, and 95% confidence interval for continuous variables, and counts, percentages, and 95% confidence intervals for categorical variables. Confidence intervals for binary endpoints were calculated using the Clopper-Pearson³⁷ exact method. A two-tailed alpha of 0.05 or smaller was considered to be statistically significant.

In relation to WBM frequency, we considered two sub-cohorts as presenting with clinically relevant bowel movement patterns at baseline, defined as children with <4 WBMs and children with <5 WBMs. This second cohort is a superset of the first. In other words, the population of children with baseline WBMs up to 4 WBMs (e.g., including 0, 1, 2, or 3) is referred to as " <4 WBMs" in accordance with the protocol primary outcome definition. The population of children with baseline WBMs up to 5 WBMs (e.g., including 0, 1, 2, 3, or 4) is referred to as " <5 WBMs."

Endpoints assessed were (i) increase of ≥ 1 WBM from baseline to day 84, (ii) increase of ≥ 2 WBMs from baseline to day 84, (iii) increase of ≥ 3 WBMs from baseline to day 84, and (iv) KINDLE quality of life (QOL questionnaire) as a standardized tool to assess adverse reactions and tolerability. We additionally measured if children with >4 WBMs experienced a change in WBM frequency as a function of treatment.

Binary endpoints (1, 2, and 3) were analyzed by logistic regression, with adjustment for age and baseline number of WBM. The continuous endpoint 4 was analyzed with covariance (ANCOVA), with adjustment for baseline and age. Cross-tabulations of the three responder endpoints with the treatment provided counts and percentages. Summary statistics were provided for a change in number of WBMs by subject groupings.

Metagenomic sequencing

Fecal samples were extracted by Diversigen with PowerSoil Pro (Qiagen) automated for high throughput on the QiaCube HT (Qiagen), using Powerbead Pro Plates (Qiagen) with 0.5 and 0.1 mm ceramic beads. Samples were quantified with Quant-iT PicoGreen dsDNA Assay (Invitrogen). Libraries were prepared with a procedure adapted from the Illumina DNA Prep kit (Illumina) and sequenced on an Illumina NovaSeq using paired-end 2×150 reads (Illumina) targeting a mean read depth of at least 4 million reads per sample.

Diversity and microbiome feature abundance quantification

All shotgun metagenomic sequencing was quality-controlled prior to analysis. We executed all quality control with a combination of bbtools³⁸ and Bowtie2.³⁹ We used bbmap to clump (clumpify.sh, optical=f, dupesubs=2, dedupe=t) reads and removed adapter contamination with bbduk (qout=33 trd=t hdist=1 k=27 ktrim="r" mink=8 overwrite=true trimq=10 qtrim="rl" threads=10 minlength=51 maxns=-1 minbasefrequency=0.05 ecco=f). We used repair.sh (also from bbtools, default settings), to repair any files with mismatched reads. We aligned to the human reference genome (hg38) using bowtie2 (–very-sensitive-local) to remove human sequences from stool samples. Finally, tadpole (mode=correct, ecc=t, ecco=t) was used to correct sequencing errors.

Annotation of microbial taxa, pathways, and gene family abundances was performed using MetaPhlAn3 and HUMAnN3 running the default settings.⁴⁰ For a robustness check in our diversity and richness analysis, we used Kraken2 (default settings) as an alternative method for computing the number of operational taxonomic units (OTUs) in each sample.⁴¹ We used Bracken to compute the abundances of each OTU at each taxonomic stratification (phyla, classes, orders, families, genera, species).⁴²

Shannon and Simpson diversity were computed for each phylogenetic level with the vegan package in R.⁴³ We computed taxonomic richness by summing the total number of observed taxonomic units for a given phylogenetic level (e.g., the total number of species with non-zero abundance). In accordance with the literature, we did not rarefy microbiome data prior to diversity, richness, or other analyses.⁴⁴

Quantification and comparisons of bifidogenic and probiotic strain abundance

We next aimed to compute the relative abundances of particular strains of interest in our active versus treatment metagenomes at baseline and endpoint. Specifically, these organisms were (i) microbial strains administered in the active formulation, and, (ii) all members of the *Bifidobacterium* genus (NCBI taxid = 1678) with representative genomes in NCBI's assembly database. This enabled us to assess a potential bifidogenic effect. We acquired the microbial genome sequences from both the original groups involved in strain isolation as well as from NCBI's assembly database.

We used a portion of Anvi'o's metapangenomic workflow^{45,46} to compute the abundance of each microbial genome in our sequenced and quality-controlled metagenomic data. This approach consists of quantifying the abundance of each gene in a genome in a given metagenome by alignment (<https://merenlab.org/data/prochlorococcus-metapangenome/>). Due to this being a whole-genome-alignment-based approach and therefore possibly lacking the resolution to resolve strain-level differences simply based on mapped reads, we did not attempt to distinguish between genomes of the same species (i.e., *B. breve*). To determine a single summary statistic for each genome's abundance, averages across the logged (adding 0.00001 to account for zero values) total abundance of each gene were computed by Anvi'o's "anvi-script-gen-distribution-of-genes-in-a-bin" function for all genomes of interest. Specifically, the gene-by-gene abundances we used were in the GENE-COVs.txt files generated by this step.

Specifically for the *Bifidobacterium* analysis, the same approach was taken using public data from NCBI (complete genomes annotated as *Bifidobacterium*). Organisms were only selected with (i) a different species-level annotation than any of the members of the administered consortia and (ii) at least 50% of the genes in their genome represented in at least

three samples (i.e., having non-zero abundance). This removed 81 genomes from those downloaded from NCBI. Subsequently, Anvi'o was employed to compute the abundance of each of these genomes in the dataset.

Metagenome association study (MAS) on microbiome feature abundances

We executed a MAS between microbial feature (i.e., taxon/pathway) abundance and responder status, treatment, bloating, pain, and weekly/change in bowel movements. We looked at associations between these clinical variables and microbial feature abundances at baseline/endpoint where relevant (e.g., we did not compute the association between endpoint microbiome abundances and baseline WBMs). Prior to running the analysis, we took the natural log of all microbiome features and added a fudge factor of 0.00001. We additionally removed features that occurred in fewer than three samples.

For binary outcome variables, we used logistic regression adjusted for baseline WBMs and age. For all other regressions (with continuous dependent variables), we used linear regression with a Gaussian link function. The only exception to our adjusting strategy was when baseline weekly WBMs were the outcome variable, in which case we did not include it as an independent variable as well. For each dependent variable, we adjusted for multiple hypothesis correction using the Benjamini–Yekutieli procedure.

RESULTS

Synbiotic use increases weekly bowel movements in constipated children compared to placebo

We aimed to estimate the increase in WBMs across the entire cohort, including both constipated and non-constipated individuals. We recruited 121 individuals, 30 of which were excluded prior to the study beginning (see Methods). A total of 64 (33 active and 31 placebo) returned for the day 84 timepoint (Fig. 1, Table 1, and Supplementary Table S1). Logistic regression adjusted for age and baseline WBMs was used to measure the change in constipation in the placebo versus treatment groups (Table 2 and Fig. 2). We stratified outcomes by changes in WBMs between baseline and day 84, comparing those who (i) experienced increased WBMs by at least one relative to baseline (1 WBM), (ii) two relative to baseline (2 WBM), and/or (iii) three relative to baseline (3 WBM). Across the entire cohort, we were unable to identify significant differences between placebo and treatment participants for any of these three cutoffs, indicating that healthy individuals did not experience a further increase in WBMs (Fig. 2).

We aimed to test if treatment improved bowel movement frequency in the 21 children with constipation as defined by <4

WBMs. Overall, 61.5% of individuals in this sub-cohort of the treatment group experienced an increase of at least 1 WBM (compared to 25% in the placebo group). We identified statistically significant, positive associations between treatment and increase in bowel movement frequency at 2 WBMs ($p = 0.0398$). By this metric, 8 individuals in the active improved, whereas only 1 in the placebo group did. Increases of 1 WBM and 3 WBMs were trending toward statistical significance (1 WBMs: $p = 0.104$; 3 WBMs $p = 0.0612$).

We executed one final analysis on the cohort of individuals <5 WBMs at baseline ($N = 38$, 19 active, 19 placebo). Within the treatment group, 63.2% of subjects experienced an improvement of at least 1 WBM (compared to 36.8% within the placebo arm). A total of 42.1% of participants in the treatment arm experienced an increase of at least 3 WBMs (compared to 10.5% in the placebo arm). We identified positive, statistically significant associations between treatment and increases in WBMs in the 2 WBM ($p = 0.034$) and 3 WBM endpoints ($p = 0.048$).

Increased abundance of the administered probiotic species in the treatment arm

We next aimed to investigate microbiome changes as a function of treatment and response to treatment. We received stool samples from 52 individuals at both the baseline and day 84 timepoints. We carried out shotgun sequencing on these samples in an effort to estimate their microbiome composition as a function of treatment and changes in constipation.

We queried if the eight microbial species present in the intervention were detectable at greater abundances in the treatment versus the placebo group at the trial endpoint (Fig. 1). We aligned quality-controlled metagenomic sequencing reads to the open-reading frames (ORFs) in each strain's draft genome and computed the overall average relative abundance of ORFs on a per-organism standpoint. We found no statistically significant shifts in species abundance between baseline and endpoint in the placebo group. By contrast, we detected statistically significant ($p < 0.05$) shifts in species abundance between baseline and endpoint for seven out of eight probiotic species in the treatment group (Fig. 3a) with the eighth species (*L. salivarius*) trending toward significance ($p = 0.059$).

We performed a similar analysis to test if the administration of the synbiotic yielded an increase in the abundance of *Bifidobacterium* species after treatment compared to placebo. We focused on the differential detection of species other than those in the intervention consortia, selecting only for *Bifidobacterium* species where >50% of the genomes were detected in three or more samples. This yielded

Table 2. Response rate and analyses of clinical outcomes.

Sample	Endpoint	Total patients	Response (%)		P value
			Intervention	Placebo	
Constipated (0–4 WBMs)	≥1 WBM increase	21 (13 active, 8 placebo)	62	25	0.104
Constipated (0–4 WBMs)	≥2 WBM increase	21 (13 active, 8 placebo)	62	13	0.0398*
Constipated (0–4 WBMs)	≥3 WBM increase	21 (13 active, 8 placebo)	54	13	0.0612
Constipated (0–5 WBMs)	≥1 WBM increase	38 (19 active, 19 placebo)	63	37	0.0877
Constipated (0–5 WBMs)	≥2 WBM increase	38 (19 active, 19 placebo)	63	32	0.0342*
Constipated (0–5 WBMs)	≥3 WBM increase	38 (19 active, 19 placebo)	42	11	0.0483*
Not constipated ≥5 WBMs	≥1 WBM increase	26 (14 active, 12 placebo)	36	58	0.171
Not constipated ≥5 WBMs	≥2 WBM increase	26 (14 active, 12 placebo)	36	33	0.8855
Not constipated ≥5 WBMs	≥3 WBM increase	26 (14 active, 12 placebo)	21	25	0.6628
Full cohort	≥1 WBM increase	64 (33 active, 31 placebo)	52	45	0.7306
Full cohort	≥2 WBM increase	64 (33 active, 31 placebo)	52	32	0.1654
Full cohort	≥3 WBM increase	64 (33 active, 31 placebo)	33	16	0.1473

* $p < 0.05$.




Fig. 2 Response rate as a function of treatment and patient cohort. *P* values correspond to those resulting from the logistic regression outputs described in Table 2.

a total of four species of interest that were not present in the intervention (in addition to two that were). None of the species not present in the intervention significantly changed in overall genome abundance between the baseline and endpoint timepoints in the placebo group, whereas only one (*B. bifidum*) approached significance (Wilcoxon $p = 0.053$) in the treatment group (Supplementary Fig. S2).

Limited features are significantly altered in treatment or constipation-associated phenotypes in this study

Via a discovery-driven MAS, we aimed to determine if the abundance of specific taxonomies or pathways was altered at baseline versus the endpoint as a function of treatment, bloating, pain, and WBMs. Adjusting for age and baseline WBMs, we used logistic regression to evaluate the association between baseline abundance of each microbiome taxonomic group across phylogenies as well as pathways identified in our sequencing data. We identified substantial heterogeneity in our cohort in these microbial feature abundances, so we only analyzed pathways and taxa that occurred in ten or more samples, yielding a total of 185 taxa and 2213 pathways. Within these, we identified one statistically significant relationship after correcting for multiple hypothesis testing: a decreased abundance of *Gemmiger formicilis* in individuals with lower WBMs at the trial endpoint (beta coefficient = -1.02, q value = 0.008). Otherwise, no taxa or pathway abundances were significantly associated with any clinical outcome variable after adjusting for false discovery rate (Supplementary Table S2 and Supplementary Fig. S3).

We additionally computed beta diversity between individuals in the treatment group at all phylogenetic levels (using MetaPhlAn3 output) and did not observe clear stratification by treatment status (Supplementary Fig. S4).

Response rate to probiotic treatment is contingent upon species richness

We next computed alpha diversity using Shannon, Simpson, and taxonomic richness metrics at the phylum, class, order, family,

genus, and species levels for all samples. This was done using Wilcoxon tests to compare variation in each of these three metrics between baseline and endpoint for non-responders and responders as well as individuals in the placebo group who both did or did not improve without treatment. Responders were defined as all individuals who received treatment and experienced an increase in WBMs of ≥ 1 . We did not see any association between response to treatment and Shannon or Simpson diversity.

However, we found that baseline richness of multiple phylogenetic levels (family, order, class, and phylum, $p < 0.05$ in all cases) discriminated between responders versus non-responders in the treatment group (Fig. 3b). For these phylogenetic groups, we additionally identified that richness increased between the baseline and endpoint timepoints ($p < 0.05$ in all cases, Supplementary Fig. S5). Endpoint richness was not significantly different between responders and non-responders. We did not find that baseline richness could discriminate between individuals who received the placebo and improved on their own, nor did richness significantly change between baseline and endpoint for these individuals.

We next stress-tested the ability of richness to discriminate between responders and non-responders using both alternative modeling approaches and a different method for quantifying taxonomic abundance within metagenomes (Kraken2/Bracken as opposed to MetaPhlAn3). We defined responders as individuals who received treatment and experienced an increase in WBMs of ≥ 1 . In addition, to account for potential confounding factors, we tested the association between richness at each phylogenetic level and responder status using a logistic regression approach adjusted for baseline WBMs, sex, and age. The association between responder status and richness was still either significant or trending for all groups ($p < 0.05$ or $p < 0.1$, Supplementary Table S3). The Kraken2/Bracken analysis yielded similar results (Supplementary Fig. S6) to MetaPhlAn3. We additionally used a logistic regression approach to evaluate the Kraken2/Bracken output and once more confirmed the significance of the association between richness and treatment response (Supplementary Table S3).




Fig. 3 Microbiome changes as a function of treatment and response. **a** Strain relative abundance before and after treatment (grouped by species). Detection of species at baseline vs. endpoint in the treatment vs placebo groups. **b** Difference in baseline microbial richness (at the order level) as a function of response rate. P value derived from a Wilcox test. Responders were defined as being in the treatment group and having at least one WBM increase.

DISCUSSION

This placebo-controlled, randomized clinical trial demonstrated that a novel synbiotic formulation increased weekly WBM in children who had low-frequency WBMs at baseline. We additionally characterized the microbiome in individuals who received and responded to treatment versus those who did not, identifying microbial richness as an indicator of a high likelihood of response to treatment. Only a fraction of studies that evaluate the impact of microbial therapy on human health is executed in a placebo-controlled or randomized setting. While useful in many ways, non-randomized study designs are not able to test a fundamental causal link between treatment and disease. Moreover, high placebo response rates are typically observed in gastrointestinal trials with subjective endpoints due to the potential effects of stress, belief, and other psychosomatic influences on the gastrointestinal system and symptomology.⁴⁷ In the case of adult IBS, for example, placebo response rates up to 40% are typically observed.⁴⁸

Children with low WBMs at baseline (defined as <4 WBMs) taking the synbiotic experienced a response rate comparable to trials testing the impact of fiber-based and laxative interventions on pediatric constipation. For example, a placebo-controlled recent study on polyethylene glycol reported a response rate of up to 77% and a placebo response rate of 42%.⁴⁹ These values are comparable to our reported treatment and placebo response rates (e.g., 62 and 13%, respectively, in the constipated, 2 WBM cohort). Our results were additionally similar to trials testing laxatives and other dietary interventions.^{50,51}

Our cohort had two major drawbacks: (i) like other recent efforts in this field,⁵² a number of non-constipated individuals not meeting our definition of constipation enrolled at baseline due to discrepancies between parental reporting of constipation and our clinical trial's definition of constipation (being <4 WBMs), and (ii) a high placebo response rate. Looking at the full cohort, we found a significant increase in the number of WBMs for both placebo and active. Having a statistically significant improvement in the placebo arm, generally referred to as a placebo effect, makes it more difficult to show superiority in the active arm. It is additionally worth noting that placebos are difficult to design for microbiome clinical trials; for example, maltodextrin placebos (like the one used here) may have an impact on the gut microbiota, yielding a placebo response rate and raising the difficulty of observing a statistically significant response in the active group.^{53,54} Despite these limitations, however, we still observed a statistically significant response to treatment when considering the constipated cohorts, whereas non-constipated individuals taking the intervention experienced no significant change in WBMs as a function of treatment.

We also note that defining constipation as <4 WBMs is specific to this study and the clinical trial it represents. While we claim WBMs at frequencies of <4 WBMs are clinically relevant, other definitions of constipation, which include even lower WBMs, do exist.⁵⁵ Future, larger, studies, should aim to further test treatments in individuals that meet these criteria.

In addition, one further limitation is that our analysis is based on a single nine-strain synbiotic composition administered to children. Patterns of microbial persistence upon use of other probiotic strains, or by populations not present in our study, such as infants, adults, and individuals with preexisting medical conditions warrant further prospective human research. Also, bifidobacterial growth, strain persistence, and correlation with richness cannot be tied to individual strains, dosages, methods of delivery, or any other single feature of microbial therapy.

This study expands our knowledge by employing several bioinformatics-based techniques to evaluate the effect of a rationally defined multi-species, multistrain synbiotic in a pediatric population. We found no indication that the intervention adversely affected children and there were no reported adverse

effects, increases in symptom severity, or dropouts related to tolerability. Due to the impact of constipation on the overall quality of life, it is encouraging that statistically significant improvements in ≥ 2 and ≥ 3 WBMs were found in constipated children, a response that we believe a medical practitioner would consider clinically relevant.

We also were able to show that treatment affected individuals' microbial gene composition. Specifically, in those who received treatment, we observed an increase in specific bifidobacteria, including the persistence of all probiotic species over time. This was observed despite substantial heterogeneity in taxonomic signatures at baseline, and we did not see the same effect in the placebo group.

Furthermore, despite limited individual microbial taxa being associated with clinical phenotypes check large, we observed the ability of microbial richness to potentially predict response to treatment across multiple phylogenetic levels, modeling approaches, and taxonomic characterization methods. Shannon and Simpson diversity were not indicative of response. This yields implications for designing future trials related to personalized response based on an individual's baseline microbiota. We hypothesize that the greater species richness is likely to translate directly into a greater variation of functional traits and depletion of available resources, resulting in the competitive exclusion of exogenous bacteria. Although other groups have reported personalized responses and resistance to microbial therapy, the problem of identifying those individuals with a tractable set of indicators who are most likely to benefit remains open.⁵⁶ We propose investigating richness as this indicator and hypothesize that the presence of potentially similar organisms or traits decreases the relative fitness and colonization opportunities of microbial therapy.

DATA AVAILABILITY

All software used in this project is available at <https://github.com/b-tierney/pds08>. Due to the clinical nature of this study, we have uploaded de-identified, raw sequencing reads with human reads removed, to NCBI BioProject ID PRJNA826535.

REFERENCES

- Manor, O. et al. Health and disease markers correlate with gut microbiome composition across thousands of people. *Nat. Commun.* **11**, 5206 (2020).
- Shanahan, F., Ghosh, T. S. & O'Toole, P. W. The healthy microbiome-what is the definition of a healthy gut microbiome? *Gastroenterology* **160**, 483–494 (2021).
- Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. *Science* **336**, 1262–1267 (2012).
- Zhu, L. et al. Structural changes in the gut microbiome of constipated patients. *Physiol. Genomics* **46**, 679–686 (2014).
- Tian, H., Chen, Q., Yang, B., Qin, H. & Li, N. Analysis of gut microbiome and metabolic characteristics in patients with slow transit constipation. *Dig. Dis. Sci.* **66**, 3026–3035 (2021).
- Chen, Y.-R. et al. High *Oscillospira* abundance indicates constipation and low BMI in the Guangdong Gut Microbiome Project. *Sci. Rep.* **10**, 9364 (2020).
- Avelar Rodriguez, D., Popov, J., Ratcliffe, E. M. & Toro Monjaraz, E. M. Functional constipation and the gut microbiome in children: preclinical and clinical evidence. *Front. Pediatr.* **8**, 595531 (2020).
- de Moraes, J. G. et al. Fecal microbiota and diet of children with chronic constipation. *Int. J. Pediatr.* **2016**, 6787269 (2016).
- de Meij, T. G. J. et al. Characterization of microbiota in children with chronic functional constipation. *PLoS One* **11**, e0164731 (2016).
- Santucci, N. R. et al. Non-pharmacologic approach to pediatric constipation. *Complement. Ther. Med.* **59**, 102711 (2021).
- Pijpers, M. A. M., Bongers, M. E. J., Benninga, M. A. & Berger, M. Y. Functional constipation in children: a systematic review on prognosis and predictive factors. *J. Pediatr. Gastroenterol. Nutr.* **50**, 256–268 (2010).
- Dimidi, E., Mark Scott, S. & Whelan, K. Probiotics and constipation: mechanisms of action, evidence for effectiveness and utilisation by patients and healthcare professionals. *Proc. Nutr. Soc.* **79**, 147–157 (2020).
- Francavilla, R. et al. A randomized controlled trial of *Lactobacillus* GG in children with functional abdominal pain. *Pediatrics* **126**, e1445–e1452 (2010).

14. Kwoji, I. D., Aiyegoro, O. A., Okpeku, M. & Adeleke, M. A. Multi-strain probiotics: synergy among isolates enhances biological activities. *Biology* **10**, 322 (2021).
15. Dimidi, E., Christodoulides, S., Scott, S. M. & Whelan, K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. *Adv. Nutr.* **8**, 484–494 (2017).
16. Closa-Monasterolo, R. et al. The use of inulin-type fructans improves stool consistency in constipated children. A randomised clinical trial: pilot study. *Int. J. Food Sci. Nutr.* **68**, 587–594 (2017).
17. Waligora-Dupriet, A.-J. et al. Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care centre. *Int. J. Food Microbiol.* **113**, 108–113 (2007).
18. Brunser, O. et al. Effect of a milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. *Pediatr. Res.* **59**, 451–456 (2006).
19. Hume, M. P., Nicolucci, A. C. & Reimer, R. A. Prebiotic supplementation improves appetite control in children with overweight and obesity: a randomized controlled trial. *Am. J. Clin. Nutr.* **105**, 790–799 (2017).
20. Abrams, S. A., Griffin, I. J. & Hawthorne, K. M. Young adolescents who respond to an inulin-type fructan substantially increase total absorbed calcium and daily calcium accretion to the skeleton. *J. Nutr.* **137**, 2524S–2526S (2007).
21. Meyer, D. & Stasse-Wolthuis, M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. *Eur. J. Clin. Nutr.* **63**, 1277–1289 (2009).
22. Scott, K. P., Martin, J. C., Duncan, S. H. & Flint, H. J. Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro. *FEMS Microbiol. Ecol.* **87**, 30–40 (2014).
23. De Vuyst, L. & Leroy, F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifidobacterial competitiveness, butyrate production, and gas production. *Int. J. Food Microbiol.* **149**, 73–80 (2011).
24. Bu, L.-N., Chang, M.-H., Ni, Y.-H., Chen, H.-L. & Cheng, C.-C. *Lactobacillus casei rhamnosus* Lcr35 in children with chronic constipation. *Pediatr. Int.* **49**, 485–490 (2007).
25. Mai, T. T. et al. Efficacy of probiotics on digestive disorders and acute respiratory infections: a controlled clinical trial in young Vietnamese children. *Eur. J. Clin. Nutr.* **75**, 513–520 (2021).
26. Indrio, F. et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. *JAMA Pediatr.* **168**, 228–233 (2014).
27. Miller, L. E., Ouwehand, A. C. & Ibarra, A. Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials. *Ann. Gastroenterol. Hepatol.* **30**, 629–639 (2017).
28. Loening-Baucke, V., Miele, E. & Staiano, A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. *Pediatrics* **113**, e259–e264 (2004).
29. Moraes, M. B., Vitolo, M. R., Aguirre, A. N. & Fagundes-Neto, U. Measurement of low dietary fiber intake as a risk factor for chronic constipation in children. *J. Pediatr. Gastroenterol. Nutr.* **29**, 132–135 (1999).
30. Kranz, S., Brauchla, M., Slavin, J. L. & Miller, K. B. What do we know about dietary fiber intake in children and health? The effects of fiber intake on constipation, obesity, and diabetes in children. *Adv. Nutr.* **3**, 47–53 (2012).
31. Ford, A. C. et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. *Am. J. Gastroenterol.* **109**, 1547–1561 (2014).
32. Jin, L. et al. Systematic review and meta-analysis of the effect of probiotic supplementation on functional constipation in children. *Medicine* **97**, e12174 (2018).
33. Pärtty, A., Rautava, S. & Kalliomäki, M. Probiotics on pediatric functional gastrointestinal disorders. *Nutrients* **10**, 1836 (2018).
34. Wojtyniak, K. & Szajewska, H. Systematic review: probiotics for functional constipation in children. *Eur. J. Pediatr.* **176**, 1155–1162 (2017).
35. Rodriguez, R. N. SAS. *Wiley Interdiscip. Res. Comput. Stat.* **3**, 1–11 (2011).
36. Team, R. C. R. *A Language and Environment for Statistical Computing*. r.meteo.uni.wroc.pl.
37. Clopper, C. J. & Pearson, E. S. The use of confidence or fiducial limits illustrated in the case of the binomial. *Biometrika* **26**, 404–413 (1934).
38. Bushnell, B. BBTools software package. <http://sourceforge.net/projects/bbmap> 578, 579 (2014).
39. Yost, S., Duran-Pinedo, A. E., Teles, R., Krishnan, K. & Frias-Lopez, J. Functional signatures of oral dysbiosis during periodontitis progression revealed by microbial metatranscriptome analysis. *Genome Med.* **7**, 27 (2015).
40. Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. *Elife* **10**, e65088 (2021).
41. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. *Genome Biol.* **20**, 257 (2019).
42. Lu, J., Breitwieser, F. P., Thielen, P. & Salzberg, S. L. Bracken: estimating species abundance in metagenomics data. *PeerJ Comput. Sci.* **3**, e104 (2017).
43. Dixon, P. VEGAN, a package of R functions for community ecology. *J. Veg. Sci.* **14**, 927–930 (2003).
44. McMurdie, P. J. & Holmes, S. Waste not, want not: why rarefying microbiome data is inadmissible. *PLoS Comput. Biol.* **10**, e1003531 (2014).
45. Delmont, T. O. & Eren, A. M. Linking pangenomes and metagenomes: the *Prochlorococcus* metapangenome. *PeerJ* **6**, e4320 (2018).
46. Utter, D. R., Borisy, G. G., Eren, A. M., Cavanaugh, C. M. & Mark Welch, J. L. Metapangenomics of the oral microbiome provides insights into habitat adaptation and cultivar diversity. *Genome Biol.* **21**, 293 (2020).
47. Enck, P. & Klosterhalfen, S. Placebo responses and placebo effects in functional gastrointestinal disorders. *Front. Psychiatry* **11**, 797 (2020).
48. Ford, A. C. & Moayyedi, P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. *Aliment. Pharmacol. Ther.* **32**, 144–158 (2010).
49. Nurko, S. et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. *J. Pediatr.* **153**, 254–261 (2008). 261.e1.
50. Savino, F. et al. Efficacy and tolerability of peg-only laxative on faecal impaction and chronic constipation in children. A controlled double blind randomized study vs a standard peg-electrolyte laxative. *BMC Pediatr.* **12**, 178 (2012).
51. Voskuil, W. et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. *Gut* **53**, 1590–1594 (2004).
52. Schoemaker, M. H. et al. Prebiotic galacto-oligosaccharides impact stool frequency and fecal microbiota in self-reported constipated adults: a randomized clinical trial. *Nutrients* **14**, 309 (2022).
53. Calgaro, M. et al. Metabarcoding analysis of gut microbiota of healthy individuals reveals impact of probiotic and maltodextrin consumption. *Benef. Microbes* **12**, 121–136 (2021).
54. Almutairi, R., Basson, A. R., Wearsh, P., Cominelli, F. & Rodriguez-Palacios, A. Validity of food additive maltodextrin as placebo and effects on human gut physiology: systematic review of placebo-controlled clinical trials. *Eur. J. Nutr.* **61**, 2853–2871 <https://doi.org/10.1007/s00394-022-02802-5> (2022).
55. Drossman, D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. *Gastroenterology* <https://doi.org/10.1053/j.gastro.2016.02.032> (2016).
56. Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell* **174**, 1388–1405.e21 (2018).

AUTHOR CONTRIBUTIONS

B.T.T. led bioinformatic analysis and manuscript drafting without involvement in trial design. C.E.M. and R.D. designed the bioinformatic strategy and participated in data analysis and manuscript drafting. B.P.C. contributed to the manuscript review from a functional assessment and clinical perspective. J.V. contributed to trial conception and text review. E.K. performed bioinformatics data analyses and visualization. G.S. assisted with statistical analysis. M.P. and P.A.B. contributed to data analysis and manuscript review from a prebiotic and probiotic perspective. S.G.P. and N.V. contributed to data interpretation and manuscript review. J.F.P. contributed to the manuscript review with an emphasis on bioinformatic analysis and computational techniques related to microbiome analysis. A.F. contributed to the manuscript review from a pediatric and clinical perspective. G.A.A. contributed to the manuscript review from an informatics perspective. E.A.M. contributed to the manuscript review including pediatric and gastroenterological perspectives. J.B. provided clinical trial operations management and sample processing support. G.R. assisted with study design and manuscript writing.

FUNDING

This work was funded by Seed Health (SH). SH funding contributed towards study design, microbiome sequencing, bioinformatics, and manuscript preparation.

COMPETING INTERESTS

B.T.T. and G.S. led data analysis and were not involved in study design or trial execution. R.D. is a co-founder and CEO of Seed Health (SH) and Luca Biologics. J.V., A.F., E.A.M., C.E.M., and J.F.P. are members of the SH Scientific board. SH Scientific board members and employees hold equity positions in SH unless otherwise stated. B.T.T., G.S., N.V., P.A.B., G.R., and E.K. are consultants for SH and were not involved in the microbial synbiotic or clinical trial design. B.T.T. additionally consults for Enzymetrics Bioscience and holds an equity position in SH. S.G.P. and G.A.G. are employed by SH and were not involved in microbial synbiotic or clinical trial design. B.P.C. receives potential royalties from the Rome Foundation for the usage of the modified Bristol Stool Form Scale for Children, which is not used in this study. A.F. is additionally a cofounder and stockholder of Alba Therapeutics, a company developing treatments complementary to the gluten-free diet by exploiting gut permeability. E.A.M. is additionally on the Scientific Advisory Board of Axial Biotherapeutics, Pendulum Therapeutics, Bloom Science, Mahana Therapeutics, APC

Ireland, Danone, and Amare. J.F.P. is the Founder and Chief Scientific Officer of Diversigen, Inc. and is on the Scientific Advisory Board for 4D Pharma, PLC. C.E.M. is cofounder of Biotia and Onegevity Health. J.V. is on the scientific advisory boards for Biomica and Plexus Worldwide.

CONSENT FOR PUBLICATION

Patient consent was required and received for this clinical trial and publication.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41390-022-02289-0>.

Correspondence and requests for materials should be addressed to Raja Dhir or Christopher E. Mason.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022